<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>中睿医药评论 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-03T23:33:35+08:00</updated>
  <subtitle>中睿咨询致力于帮助中国本土大中型企业和具备核心资源的中小成长型企业构建企业战略和战术落地高度融合的一体化的体系。推动企业在明确战略方向指引下，实现持续成长！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>先声药业12年前引进的VEGF单抗再次提交IND</title>
    <updated>2020-12-03T17:02:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/7MnShVObh1VvR_BtvIklXg</id>
    <link href="https://mp.weixin.qq.com/s/7MnShVObh1VvR_BtvIklXg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞「瑞马唑仑」第 3 个适应症报上市，2020 医保谈判进行中</title>
    <updated>2020-12-03T17:02:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/N6NMbkCxNPb2S_0SiE3tKA</id>
    <link href="https://mp.weixin.qq.com/s/N6NMbkCxNPb2S_0SiE3tKA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>三款新药拟纳入突破性治疗品种，来自诺华、云顶新耀和科济生物</title>
    <updated>2020-12-01T17:43:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/lcfDPsHu-U6orAJwtr3Deg</id>
    <link href="https://mp.weixin.qq.com/s/lcfDPsHu-U6orAJwtr3Deg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞医药「他达拉非片」获批上市</title>
    <updated>2020-11-30T19:25:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/6Epu-4d_rpqhtzFkDIAebw</id>
    <link href="https://mp.weixin.qq.com/s/6Epu-4d_rpqhtzFkDIAebw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第3家！海思科「盐酸普拉克索缓释片」获批上市并通过一致性评价</title>
    <updated>2020-11-30T19:25:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/H-_2xVHdQviLyIwmfgJtXA</id>
    <link href="https://mp.weixin.qq.com/s/H-_2xVHdQviLyIwmfgJtXA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>今日 24 个仿制药获批，3 个首家，4 个前三家</title>
    <updated>2020-11-27T17:18:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-27:/s/TrPbh9CJQ8NAN50gUUzP7A</id>
    <link href="https://mp.weixin.qq.com/s/TrPbh9CJQ8NAN50gUUzP7A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>中国在研肿瘤药创新性分析</title>
    <updated>2020-11-27T17:18:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-27:/s/oI_uXgasuYr3YXIKSAq-LQ</id>
    <link href="https://mp.weixin.qq.com/s/oI_uXgasuYr3YXIKSAq-LQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>高达7.68亿美元！复宏汉霖授权靶向EGFR和4-1BB的双特异性抗体海外权益</title>
    <updated>2020-11-26T16:55:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/2m1t1LHy-XeiflNM6VNQZg</id>
    <link href="https://mp.weixin.qq.com/s/2m1t1LHy-XeiflNM6VNQZg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>重磅！恒瑞医药卡瑞利珠单抗+苹果酸法米替尼被纳入拟突破性治疗品种公示</title>
    <updated>2020-11-26T16:55:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/SU52M_RiPp04D2A67RM3cA</id>
    <link href="https://mp.weixin.qq.com/s/SU52M_RiPp04D2A67RM3cA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国产「药王」新适应症获批，八成原研市场进一步被瓜分</title>
    <updated>2020-11-25T17:28:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/mOp1zmpKsrTRqATdIustvg</id>
    <link href="https://mp.weixin.qq.com/s/mOp1zmpKsrTRqATdIustvg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>正大天晴「注射用泮托拉唑钠」集齐4家！另有四川科伦、常州康普、扬子江等药企过评</title>
    <updated>2020-11-25T17:28:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/9nrU0UDECU7SbCRxN8wM2Q</id>
    <link href="https://mp.weixin.qq.com/s/9nrU0UDECU7SbCRxN8wM2Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州进入密集收获期，多款创新药迎来新进展...</title>
    <updated>2020-11-24T18:32:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/TbgAusYmnheFlKUIRVbjRw</id>
    <link href="https://mp.weixin.qq.com/s/TbgAusYmnheFlKUIRVbjRw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>豪森2款仿制药品种报产</title>
    <updated>2020-11-24T18:32:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/RO4MSjj3k1g7OVYfsST4PA</id>
    <link href="https://mp.weixin.qq.com/s/RO4MSjj3k1g7OVYfsST4PA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>最新！2020年全球医疗器械企业100强出炉！</title>
    <updated>2020-11-23T17:39:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/p5lADDQyMEETZxzquWO93w</id>
    <link href="https://mp.weixin.qq.com/s/p5lADDQyMEETZxzquWO93w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>多款新冠mRNA疫苗迎重要进展；FDA批准首个早衰症疗法</title>
    <updated>2020-11-23T17:39:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/VYDPhsM-0pEwEGKYOurfFg</id>
    <link href="https://mp.weixin.qq.com/s/VYDPhsM-0pEwEGKYOurfFg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>先声药业引进的1类新药获批临床，针对痛风伴高尿酸血症！</title>
    <updated>2020-11-20T15:00:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/ozKPzMser7IBCmunOQ6JuA</id>
    <link href="https://mp.weixin.qq.com/s/ozKPzMser7IBCmunOQ6JuA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>7款药物纳入第三批临床急需境外新药名单</title>
    <updated>2020-11-20T15:00:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/ZekMNaIIJ2tJ9a1_us2MDg</id>
    <link href="https://mp.weixin.qq.com/s/ZekMNaIIJ2tJ9a1_us2MDg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>刚刚！贝达药业「恩莎替尼」获批上市，首个国产 ALK 抑制剂</title>
    <updated>2020-11-19T17:16:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-19:/s/lyl6SHl1BZot9SQlBh1rPw</id>
    <link href="https://mp.weixin.qq.com/s/lyl6SHl1BZot9SQlBh1rPw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>